Literature DB >> 34981318

Cognitive Phenotypes of HIV Defined Using a Novel Data-driven Approach.

Robert H Paul1,2, Kyu Cho3, Andrew Belden3, Adam W Carrico4, Eileen Martin5, Jacob Bolzenius3, Patrick Luckett6, Sarah A Cooley6, Julie Mannarino3, Jodi M Gilman7, Mariah Miano8, Beau M Ances6.   

Abstract

The current study applied data-driven methods to identify and explain novel cognitive phenotypes of HIV.
Methods: 388 people with HIV (PWH) with an average age of 46 (15.8) and median plasma CD4+ T-cell count of 555 copies/mL (79% virally suppressed) underwent cognitive testing and 3T neuroimaging. Demographics, HIV disease variables, and health comorbidities were recorded within three months of cognitive testing/neuroimaging. Hierarchical clustering was employed to identify cognitive phenotypes followed by ensemble machine learning to delineate the features that determined membership in the cognitive phenotypes. Hierarchical clustering identified five cognitive phenotypes. Cluster 1 (n=97) was comprised of individuals with normative performance on all cognitive tests. The remaining clusters were defined by impairment on action fluency (Cluster 2; n=46); verbal learning/memory (Cluster 3; n=73); action fluency and verbal learning/memory (Cluster 4; n=56); and action fluency, verbal learning/memory, and tests of executive function (Cluster 5; n=114). HIV detectability was most common in Cluster 5. Machine learning revealed that polysubstance use, race, educational attainment, and volumes of the precuneus, cingulate, nucleus accumbens, and thalamus differentiated membership in the normal vs. impaired clusters. The determinants of persistent cognitive impairment among PWH receiving suppressive treatment are multifactorial nature. Viral replication after ART plays a role in the causal pathway, but psychosocial factors (race inequities, substance use) merit increased attention as critical determinants of cognitive impairment in the context of ART. Results underscore the need for comprehensive person-centered interventions that go beyond adherence to patient care to achieve optimal cognitive health among PWH.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cognition; HIV; Machine learning; Substance use

Year:  2022        PMID: 34981318     DOI: 10.1007/s11481-021-10045-0

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  33 in total

1.  Norms for letter and category fluency: demographic corrections for age, education, and ethnicity.

Authors:  J A Gladsjo; C C Schuman; J D Evans; G M Peavy; S W Miller; R K Heaton
Journal:  Assessment       Date:  1999-06

Review 2.  Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Am J Psychiatry       Date:  2002-10       Impact factor: 18.112

3.  Early environmental factors, ethnicity, and adult cognitive test performance.

Authors:  Desiree A Byrd; S Walden Miller; Judy Reilly; Shirley Weber; Tamara L Wall; Robert K Heaton
Journal:  Clin Neuropsychol       Date:  2006-06       Impact factor: 3.535

4.  Measurement of urinary thyroxine.

Authors:  E Black; S Griffiths; R Hoffenberg; B Leatherdale
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

5.  Cognitive Functioning in Adults Aging with HIV: A Cross-Sectional Analysis of Cognitive Subtypes and Influential Factors.

Authors:  Pariya L Fazeli; Michael Crowe; Lesley A Ross; Virginia Wadley; Karlene Ball; David E Vance
Journal:  J Clin Res HIV AIDS Prev       Date:  2014-02-18

Review 6.  Cognitive and neurobiologic markers of early Alzheimer disease.

Authors:  M S Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

7.  Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy.

Authors:  Adam W Carrico; Peter W Hunt; Torsten B Neilands; Samantha E Dilworth; Jeffrey N Martin; Steven G Deeks; Elise D Riley
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731

8.  Do the Benefits of Educational Attainment for Late-life Cognition Differ by Racial/Ethnic Group?: Evidence for Heterogenous Treatment Effects in the Kaiser Healthy Aging and Diverse Life Experience (KHANDLE) Study.

Authors:  Chloe W Eng; Medellena Maria Glymour; Paola Gilsanz; Dan M Mungas; Elizabeth R Mayeda; Oanh L Meyer; Rachel A Whitmer
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Apr-Jun 01       Impact factor: 2.703

9.  Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study.

Authors:  Rebecca E Amariglio; Rachel F Buckley; Jennifer S Rabin; Kathryn V Papp; Yakeel T Quiroz; Elizabeth C Mormino; Kathryn P Sparks; Keith A Johnson; Dorene M Rentz; Reisa A Sperling
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus-Infected Patients.

Authors:  Raha M Dastgheyb; Ned Sacktor; Donald Franklin; Scott Letendre; Thomas Marcotte; Robert Heaton; Igor Grant; Justin C McArthur; Leah H Rubin; Norman J Haughey
Journal:  J Acquir Immune Defic Syndr       Date:  2019-09-01       Impact factor: 3.771

View more
  2 in total

1.  The Interaction of HIV With Mental Health in the Modern Antiretroviral Therapy Era.

Authors:  Adam W Carrico; Leah H Rubin; Robert H Paul
Journal:  Psychosom Med       Date:  2022-10-01       Impact factor: 3.864

2.  Individual Differences in CD4/CD8 T-Cell Ratio Trajectories and Associated Risk Profiles Modeled From Acute HIV Infection.

Authors:  Robert Paul; Kyu Cho; Jacob Bolzenius; Carlo Sacdalan; Lishomwa C Ndhlovu; Lydie Trautmann; Shelly Krebs; Somporn Tipsuk; Trevor A Crowell; Duanghathai Suttichom; Donn J Colby; Thomas A Premeaux; Nittaya Phanuphak; Phillip Chan; Eugène Kroon; Sandhya Vasan; Denise Hsu; Adam Carrico; Victor Valcour; Jintanat Ananworanich; Merlin L Robb; Julie A Ake; Somchai Sriplienchan; Serena Spudich
Journal:  Psychosom Med       Date:  2022-07-06       Impact factor: 3.864

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.